The Sarcoidosis drugs in development market research report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sarcoidosis. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sarcoidosis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued products.

GlobalData tracks 16 drugs in development for Sarcoidosis by 15 companies/universities/institutes. The top development phase for Sarcoidosis is phase i with six drugs in that stage. The Sarcoidosis pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Sarcoidosis pipeline products market are: Pfizer, Novartis and Sarcomed.

The key targets in the Sarcoidosis pipeline products market include Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2), Vasoactive Intestinal Polypeptide Receptor 1 (Pituitary Adenylate Cyclase Activating Polypeptide Type II Receptor or VPAC1 or VIPR1), and DNA.

The key mechanisms of action in the Sarcoidosis pipeline product include DNA Synthesis Inhibitor with two drugs in Preclinical. The Sarcoidosis pipeline products include six routes of administration with the top ROA being Intravenous and five key molecule types in the Sarcoidosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Sarcoidosis overview

Sarcoidosis is a systemic inflammatory disease that can affect any organ. It is characterized by the development and growth of tiny lumps of cells called granulomas. The disease usually begins in the lungs, skin, or lymph nodes. The cause of sarcoidosis is unknown. Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition.

For a complete picture of Sarcoidosis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.